Cargando…

Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients

BACKGROUND: Pegylated interferon alfa plus ribavirin protocol is currently considered the most efficient hepatitis C treatment. However, no evidence of costs comparison among common viral genotypes has been published. OBJECTIVES: We aimed to assess core drivers of hepatitis C medical care costs and...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakovljevic, Mihajlo, Mijailovic, Zeljko, Popovska Jovicic, Biljana, Canovic, Predrag, Gajovic, Olgica, Jovanovic, Mirjana, Petrovic, Dejan, Milovanovic, Olivera, Djordjevic, Natasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768202/
https://www.ncbi.nlm.nih.gov/pubmed/24032044
http://dx.doi.org/10.5812/hepatmon.6750
_version_ 1782283749203902464
author Jakovljevic, Mihajlo
Mijailovic, Zeljko
Popovska Jovicic, Biljana
Canovic, Predrag
Gajovic, Olgica
Jovanovic, Mirjana
Petrovic, Dejan
Milovanovic, Olivera
Djordjevic, Natasa
author_facet Jakovljevic, Mihajlo
Mijailovic, Zeljko
Popovska Jovicic, Biljana
Canovic, Predrag
Gajovic, Olgica
Jovanovic, Mirjana
Petrovic, Dejan
Milovanovic, Olivera
Djordjevic, Natasa
author_sort Jakovljevic, Mihajlo
collection PubMed
description BACKGROUND: Pegylated interferon alfa plus ribavirin protocol is currently considered the most efficient hepatitis C treatment. However, no evidence of costs comparison among common viral genotypes has been published. OBJECTIVES: We aimed to assess core drivers of hepatitis C medical care costs and compare cost effectiveness of this treatment among patients infected by hepatitis C virus with genotypes 1 or 4 (group I), and 2 or 3 (group II). PATIENTS AND MATERIALS: Prospective bottom-up cost-effectiveness analysis from societal perspective was conducted at Infectious Diseases Clinic, University Clinic Kragujevac, Serbia, from 2007 to 2010. There were 81 participants with hepatitis C infection, treated with peg alpha-2a interferon plus ribavirin for 48 or 24 weeks. Economic data acquired were direct inpatient medical costs, outpatient drug acquisition costs, and indirect costs calculated through human capital approach. RESULTS: Total costs were significantly higher (P = 0.035) in group I (mean ± SD: 12,751.54 ± 5,588.06) compared to group II (mean ± SD: 10,580.57 ± 3,973.02). In addition, both direct (P = 0.039) and indirect (P < 0.001) costs separately were significantly higher in group I compared to group II. Separate comparison within direct costs revealed higher total cost of medical care (P = 0.024) in first compared to second genotype group, while the similar tendency was observed for total drug acquisition (P = 0.072). CONCLUSION: HCV genotypes 1 and 4 cause more severe clinical course require more care and thus incur higher expenses compared to HCV 2 and 3 genotypes. Policy makers should consider willingness to pay threshold differentially depending upon HCV viral genotype detected.
format Online
Article
Text
id pubmed-3768202
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-37682022013-09-12 Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients Jakovljevic, Mihajlo Mijailovic, Zeljko Popovska Jovicic, Biljana Canovic, Predrag Gajovic, Olgica Jovanovic, Mirjana Petrovic, Dejan Milovanovic, Olivera Djordjevic, Natasa Hepat Mon Research Article BACKGROUND: Pegylated interferon alfa plus ribavirin protocol is currently considered the most efficient hepatitis C treatment. However, no evidence of costs comparison among common viral genotypes has been published. OBJECTIVES: We aimed to assess core drivers of hepatitis C medical care costs and compare cost effectiveness of this treatment among patients infected by hepatitis C virus with genotypes 1 or 4 (group I), and 2 or 3 (group II). PATIENTS AND MATERIALS: Prospective bottom-up cost-effectiveness analysis from societal perspective was conducted at Infectious Diseases Clinic, University Clinic Kragujevac, Serbia, from 2007 to 2010. There were 81 participants with hepatitis C infection, treated with peg alpha-2a interferon plus ribavirin for 48 or 24 weeks. Economic data acquired were direct inpatient medical costs, outpatient drug acquisition costs, and indirect costs calculated through human capital approach. RESULTS: Total costs were significantly higher (P = 0.035) in group I (mean ± SD: 12,751.54 ± 5,588.06) compared to group II (mean ± SD: 10,580.57 ± 3,973.02). In addition, both direct (P = 0.039) and indirect (P < 0.001) costs separately were significantly higher in group I compared to group II. Separate comparison within direct costs revealed higher total cost of medical care (P = 0.024) in first compared to second genotype group, while the similar tendency was observed for total drug acquisition (P = 0.072). CONCLUSION: HCV genotypes 1 and 4 cause more severe clinical course require more care and thus incur higher expenses compared to HCV 2 and 3 genotypes. Policy makers should consider willingness to pay threshold differentially depending upon HCV viral genotype detected. Kowsar 2013-06-19 /pmc/articles/PMC3768202/ /pubmed/24032044 http://dx.doi.org/10.5812/hepatmon.6750 Text en Copyright © 2013, Kowsar Corp. http://creativecommons.org/licenses/by/3/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jakovljevic, Mihajlo
Mijailovic, Zeljko
Popovska Jovicic, Biljana
Canovic, Predrag
Gajovic, Olgica
Jovanovic, Mirjana
Petrovic, Dejan
Milovanovic, Olivera
Djordjevic, Natasa
Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients
title Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients
title_full Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients
title_fullStr Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients
title_full_unstemmed Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients
title_short Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients
title_sort assessment of viral genotype impact to the cost-effectiveness and overall costs of care for peg-interferon-2α + ribavirine treated chronic hepatitis c patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768202/
https://www.ncbi.nlm.nih.gov/pubmed/24032044
http://dx.doi.org/10.5812/hepatmon.6750
work_keys_str_mv AT jakovljevicmihajlo assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients
AT mijailoviczeljko assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients
AT popovskajovicicbiljana assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients
AT canovicpredrag assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients
AT gajovicolgica assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients
AT jovanovicmirjana assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients
AT petrovicdejan assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients
AT milovanovicolivera assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients
AT djordjevicnatasa assessmentofviralgenotypeimpacttothecosteffectivenessandoverallcostsofcareforpeginterferon2aribavirinetreatedchronichepatitiscpatients